

LITERATURA




1. Cifkova R, et al. 30 year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post MONICA, 1985-2016/17. PLoS One. 2020;15(5):e0232845.
2. Holland M, Lewis P. An audit and suggested guidelines for in patient blood pressure measurement. J Hypertens. 2014;32:2166-2170.
3. Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41(12):1874-2071.
4. Widimsky J, et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2022. Hypertenze Kardiovaskulární Prevence. 2022;Supplementum:25.
5. Ward AM, et al. Home measurement of blood pressure and cardiovascular disease: systematic review and meta analysis of prospective studies. J Hypertens. 2012;30(3):449-456.
6. Clement DL, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407-2415.
7. Li Y, et al. Ambulatory hypertension subtypes and 24 hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466-474.
8. Roush GC, et al. Prognostic impact from clinic, daytime, and night time systolic blood pressure in nine cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32(12):2332-2340.
9. Stergiou GS, et al. 2021 European Society of Hypertension practice guidelines for office and out of office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302.
10. Stergiou GS, et al. Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2022 Aug 1;40(8):1449-1460.
11. Afshin A, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377(1):13-27.
12. Piché ME, Tchernof A, Després JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020;126(11):1477-1500.
13. Busetto L, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024;30(9):2395-2399.
14. Vasani RS, et al. Hypertension Mediated Organ Damage: Prevalence, Correlates, and Prognosis in the Community. Hypertension. 2022;79(3):505-515.
15. Adamczak M, Surma S, Więcek A. Hyponatremia in patients with arterial hypertension: pathophysiology and management. Arch Med Sci. 2023;19(6):1630-1645.
16. Sourij C, et al. Prevalence of Undiagnosed Diabetes and Prediabetes according to Age and Obesity Status in Central Europe. Obes Facts. 2025;18(6):582-591.
17. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-3337.
18. Borghi C, et al. Adherence to Triple Single Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real World Analysis in Italy. Adv Ther. 2023;40(4):1765-1772.
19. Mancia G, et al. Two Drug Combinations as First Step Antihypertensive Treatment. Circ Res. 2019;124(7):1113-1123.
20. Rea F, et al. Early cardiovascular protection by initial two drug fixed dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-3661.
21. Gupta P, et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69(6):1113-1120.
22. Krousel Wood M, et al. A hybrid 4 item Krousel Wood Medication Adherence Scale predicts cardiovascular events in older hypertensive adults. J Hypertens. 2019;37(4):851-859.
23. Corrao G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610-618.
24. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(7):1124-1140.
25. Williams B, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug resistant hypertension (PATHWAY 2): a randomised, double blind, crossover trial. Lancet. 2015;386(10008):2059-2068.
26. Ceral J, et al. Difficult to control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non responsiveness from non adherence to recommended therapy. Hypertens Res. 2011;34(1):87-90.
27. Murray CJL, et al. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249.

Odborné informace pro vaši praxi – také na Instagramu!

SOLEN
MEDICAL EDUCATION



Sledujte nás na
@solen_cz a nechte
si předepsat
medicínu, která vás
baví: **přehledně,
pravidelně
a s respektem**
k vaší odbornosti.

-  **Zajímavosti z odborných akcí**
-  **Odemčené články a podcasty**
-  **Klinické kvízy napříč obory**
-  **Soutěže o předplatné a registrace na kongresy**



**vaše propojení
s komunitou mladých
i zkušených lékařů**

Vzděláváme, inspirujeme a propojujeme zdravotníky už čtvrt století.